Prevention and treatment of osteoporotic fractures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project focuses on osteoporotic fractures by conducting registration and follow-up studies to gather epidemiological data. It includes a prospective treatment study aimed at exploring effective treatment strategies through randomized controlled trials. The study also aims to establish a biomarker warning model using multi-omics research and develop a new imaging technology for creating an imaging omics warning model for osteoporotic refractures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. New brittle hip fractures;
2. New brittle vertebral fractures;
3. New other site fractures and/or total hip or neck of femur or L1-L4 T-value \< -1.0;
4. Men or postmenopausal women;
5. Age 45-90 years old;
6. Ability to move autonomously

Exclusion Criteria:

1. bone metabolic diseases except for osteoporosis eg. a. (Osteogenesis Imperfecta, Paget's disease, Osteomalacia), b. Cushing's syndrome, c.hyperprolactinemia;
2. Having primary hyperparathyroidism or hypothyroidism;
3. Had or have osteomyelitis of the jaw or necrosis of the jaw;
4. GFR\<30ml/min/1.73m2;
5. Active infection that requires systematic treatment;
6. Used intravenous bisphosphonate, fluoride, or strontium for osteoporosis within 2 years;
7. Used teriparatide and denosumab for osteoporosis within 6 months;
8. Used glucocorticoids (equivalent to \&gt;5 mg/day prednisone) for more than 10 days within 6 weeks;
9. The time gap between the first time and the last time oral bisphosphonate for osteoporosis less than 1 year( if used within one year, but the cumulative use is ≤ 1 month, the subject can be enrolled) ;
10. Patients with malignant tumors or bone metastases within 5 years, except tumors that are expected to be cured after treatment;
11. Have hypocalcemia and hypercalcemia;
12. Unexplained elevation of alkaline phosphatase;
13. A serious deficiency of vitamin D (25OHD \&lt;10ng/mL);
14. Patients who have previously received external radiation or radiation therapy with bone implants;
15. Uncontrolled comorbidities included heart failure above the New York cardiac Function Scale, glycosylated hemoglobin \&gt; 8.5%, and severe arrhythmias;
16. Planned pregnancy and lactation at present or during the study period;
17. Allergic to teriparatide and denosumab;
18. Participating in clinical trials of other drugs at present;
19. subjects do not suitable for this study

Where it's running

• Beijing Friendship Hospital, Capital Medical University
  Beijing, China Recruiting
• Beijing Hospital
  Beijing, China Recruiting
• Beijing Pinggu Hospital
  Beijing, China Recruiting
• Beijing Shijingshan Hospital
  Beijing, China Recruiting
• Beijing Yanhua Hospital
  Beijing, China Recruiting
• Peking Union Medical College Hospital
  Beijing, China Recruiting

+8 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Weibo Xia
• Email: xiaweibo8301@163.com
• Phone: 13501002126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ibandronate vs. Zoledronic Acid After Denosumab: Is Either Equal for Postmenopausal Osteoporosis?

  In postmenopausal osteoporosis, this study tests whether intravenous ibandronate given after stopping denosumab works as well as zoledronic acid over a year.

  Recruiting Phase 4 National Taiwan University Hospital · Taipei · NCT07406685

• Romosozumab and denosumab alone or together for postmenopausal osteoporosis

  This 6-month pilot tests whether cyclic romosozumab combined with denosumab improves bone density more than denosumab alone in postmenopausal women with osteoporosis.

  Recruiting Phase 4 National Taiwan University Hospital · Douliu, Taiwan · NCT07283887

• Denosumab effects on muscle strength and insulin sensitivity

  This trial will test whether denosumab improves muscle strength and insulin sensitivity in postmenopausal women with osteoporosis and type 2 diabetes who are taking metformin.

  Recruiting Phase 4 Aarhus University Hospital · Aarhus · NCT07271771

• Combining PD-1 immunotherapy, denosumab, and chemotherapy for advanced non-squamous lung cancer without targetable mutations

  This trial will test whether adding a PD-1 immunotherapy and denosumab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer who do not have targetable driver mutations.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07034391

• Using an osteoporotic fracture score to guide treatment for thoracic and lumbar spine fractures

  This study will try using the OF (osteoporotic fracture) score to help doctors decide between surgery and non-surgical care for older adults with painful thoracic or lumbar osteoporotic fractures.

  Recruiting at 3 sites AO Foundation, AO Spine · San Francisco, California and 14 other locations · NCT07027306

• Comparing two treatment regimens for osteoporosis in postmenopausal women

  This study is testing two different treatment plans for osteoporosis in postmenopausal women to see which one helps improve bone strength and reduce the risk of fractures better.

  Recruiting Phase 4 National Taiwan University Hospital · Taipei · NCT06938152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.